Joachim M Baehring MD

Associate Professor of Medicine (Medical Oncology), of Neurology and of Neurosurgery; Clinical Program Leader, Brain Tumor Program, Smilow Cancer Hospital

Specialties & Subspecialties

Cancer Center, Yale: Brain Tumor Center | Hematology Program

Neurology: Stroke Center, Yale-New Haven | Brain Tumors and Neuro-Oncology

Neurosurgery: Neuro-Oncology

Education & Training

  • M.D., Johannes-Gutenberg-University of Mainz (1994)
  • Fellow, University Hospital Heidelberg / Germany , Molecular Oncology (1994 - 1996)
  • Intern, Medical College of Pennsylvania/Philadelphia, PA , Internal Medicine (1996 - 1997)
  • Resident, Hahnemann University Hospital Philadelphia, PA , Neurology (1997 - 2000)
  • Fellow, Massachusetts General Hospital, Boston, MA , Neuro-Oncology (2000 - 2002)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients


Clinical Interests

Chemotherapy of primary brain tumors (high-grade gliomas, central nervous system lymphoma); neurological complications of brain cancer; general neurology; molecular markers of cancer.


Cancers Treated

Brain


Board Certifications

  • Neurology, Board Certified (2001)

Clinical Trials

ConditionsStudy Title
Breast Cancer (ER, PR, and HER2 negative), Colorectal Cancer, Endometrial Cancer, Gastric Adenocarcinoma, Glioblastoma Multiforme, Head/ Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Prostate Cancer, Brain and Nervous System, Breast - Female, Breast - Male, Colon, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Female Genital, Ovary, Prostate, Rectum, and StomachA Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
Brain and Nervous SystemA Randomized Phase IIB Study of Nivolumab or Nivolumab in Combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma

Edit Profile